Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is used for consolidation in children and adolescents with refractory or early relapsed ALK (anaplastic lymphoma kinase)-positive anaplastic large cell lymphoma (ALCL). The immune system plays a major role in sustained disease control. We retrospectively analyzed whether conditioning, donor type, and in vivo T-cell depletion correlate with outcome in a population-based cohort of 57 children with central nervous system (CNS)-negative ALCL relapse who received HSCT between 2005 and 2022. Progression-free survival (PFS) and overall survival from transplantation were 84% ± 10% and 91% ± 8% at 3 years, respectively. Conditioning was based on total body irradiation (TBI) in 30 patients and on chemotherapy in 27 patients, mainly with reduced-toxicity conditioning (treosulfan, fludarabine, and thiotepa). PFS and graft-versus-host disease (GVHD)-free and event-free survival (GEFS) were comparable between TBI and chemotherapy, 87% ± 6% vs 81% ± 8% (P = .62) and 67% ± 9% vs 74% ± 8% (P = .63), respectively. Patients with transplantation from unrelated donors with rabbit anti-human T lymphocyte globulin (ATLG) had superior PFS and GEFS than those receiving grafts from matched siblings without ATLG: 94% ± 7% vs 67% ± 22% (P = .0007) and 82% ± 13% vs 44% ± 24% (P = .011), respectively. Progression during frontline chemotherapy, minimal residual disease, and remission status at HSCT were not associated with outcome. Nonrelapse mortality was 5.6% for all 65 patients, and cumulative incidence of grade 2 to 4 acute GVHD was 25%. Our data supports the use of TBI-free conditioning and suggest improved outcomes with unrelated donors receiving ATLG prophylaxis.